Evidence map›Paper›PMID 40750712›Full record

ArticleClinical journal of gastroenterology2025

Fatal portal vein thrombosis following combination therapy with atezolizumab plus bevacizumab for hepatocellular carcinoma: an autopsy case report.

Yutaro Mihara, Yu Noda, Kotaro Iemura, Miwa Sakai, Hideki Iwamoto, Reiichiro Kondo, Takashi Niizeki, Hironori Kusano, Takumi Kawaguchi, Jun Akiba

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Clinical journal of gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yutaro MiharaDepartment of Pathology and Laboratory Medicine, Kurume University Medical Center, 155-1 Kokubu-Machi, Kurume, 839-0863, Japan. mihara_yuutarou@kurume-u.ac.jp.ORCID http://orcid.org/0000-0002-4119-1486
Yu NodaDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Kotaro IemuraDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Miwa SakaiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Hideki IwamotoDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Reiichiro KondoDepartment of Pathology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Takashi NiizekiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Hironori KusanoDepartment of Pathology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Takumi KawaguchiDivision of Gastroenterology, Department of Medicine, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.
Jun AkibaDepartment of Pathology, Kurume University School of Medicine, 67 Asahi-Machi, Kurume, 830-0011, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This case report describes a 77-year-old man with chronic hepatitis C-related hepatocellular carcinoma who developed severe portal vein thrombosis after combination therapy with atezolizumab (ATZ) plus bevacizumab (BEV). Following treatment, he experienced abdominal distension and subsequent deterioration, leading to hospitalization. Despite intensive care, including anticoagulation therapy, the patient succumbed to multi-organ failure. An autopsy revealed intestinal necrosis, along with severe thrombosis of the portal vein and superior mesenteric vein. This case highlights a rare but serious risk of portal vein thrombosis associated with ATZ plus BEV therapy, underscoring the need for vigilant monitoring in patients receiving this treatment.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, HepatocellularLiver NeoplasmsPortal VeinVenous ThrombosisAgedAutopsyFatal OutcomeHepatitis C, ChronicHumansMaleAntibodies, Monoclonal, HumanizedatezolizumabBevacizumabAtezolizumabBevacizumabCombination therapyHepatocellular carcinomaPortal vein thrombosis

Identifiers

PMID40750712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.